ESPR
Esperion Therapeutics Inc.
Halal Rating :
Last Price
$2.20
Last updated:
Market Cap
-
7D Change
-3.51%
1 Year Change
2.33%
Company Overview
Industries
Exchange
Next Earnings Date
Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The company's main products include NEXLETOL® (bempedoic acid) tablet and NEXLIZET® (bempedoic acid and ezetimibe) tablet, both approved by the FDA for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $51.63m | $82.74m | - | $15.08m | 0.00% | 18.23% |
| June 30, 2024 | $73.83m | $138.21m | - | $66.96m | 0.00% | 48.45% |
| March 31, 2024 | $137.74m | $79.49m | - | $14.02m | 0.00% | 17.64% |
Company Impact
Help us evaluate Esperion Therapeutics Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.